NEW YORK/LONDON (Reuters) -GSK CEO Emma Walmsley gave an upbeat assessment of the British drugmaker's new respiratory ...

Pregnant women and their babies and adults over 60 years old can be more protected from respiratory syncytial virus, or RSV, ...

RSV is a leading cause of pneumonia in toddlers and the elderly and GSK's shot, branded Arexvy, "will be more than a billion pounds in its first ... our RSV vaccine," Walmsley said in the interview.

Federal officials have been working with companies to find ways to boost the supply of the new vaccine for newborns.

The U.S. launch of the vaccine has so far reached three million of the more than 80 million adults over 60 at risk from RSV, ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Ethris’s Phase I trial to investigate its ...

The EU's medicines regulator today recommended approval ... The EMA's recommendation comes three weeks after the vaccine was approved by the U.K.'s medicines regulator — the first country in the world ...

One vaccine dose is certainly better than none. But is it enough to let someone travel? That’s one of the major questions EU countries will need to decide upon as they thrash out the details of ...

The Coalition for Epidemic Preparedness Innovations (CEPI), Gavi, the Vaccine Alliance ... more than a month after the first COVID-19 vaccine received WHO EU approval. The purpose of sharing ...

RSV vaccines are dwindling as cases continue to rise. Here's what you need to know about the RSV vaccine shortage and how you ...